ABBV AbbVie
An immunology cash machine whose price already assumes Skyrizi and Rinvoq keep executing flawlessly for a decade.
The story
AbbVie got through the Humira biosimilar cliff faster than expected. Skyrizi and Rinvoq are now growing at double-digit rates and should together pass $31B by 2027, while neuroscience (Vraylar, migraine drugs, Parkinson's) adds a second growth leg. It is a mature, cash-rich pharma franchise. Reported margins look low because of Allergan intangible amortization and in-process R&D (IPR&D) charges from frequent business-development deals. The moat lasts as long as the immunology patents and depends on deals refilling the pipeline before the late-2030s exclusivity losses.
Trailing revenue rose about 5% to $64.4B and 2026 guidance points to high-single-digit growth, so Y1 growth moves from 8% to 9%. Target margin moves from 36% to 42% (about 17% relative, below the 20% threshold): adjusted operating margins run around 46%, Allergan amortization is fading, and I subtract roughly 4 points for recurring IPR&D and business-development spending, which is real reinvestment. Beta, sales-to-capital, horizon and terminal growth are unchanged; the last price-to-value gap of nearly 3x (well over 100%) forced a re-check, but only the margin evidence justifies a move.
Value drivers
| Revenue growth (Y1) | 9.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 10y |
| Target operating margin | 42.0% |
| Years to target margin | 4 |
| Sales-to-capital | 1.40 |
| Beta | 0.90 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.6% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 122.37B |
| PV of terminal value | 165.34B |
| Equity value | 223.14B |
| ÷ shares → per share | $126.28 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 70.18B | 9.0% | 24.0% | 10.96B | 4.14B | 6.82B | 6.28B |
| 2 | 75.99B | 8.3% | 30.0% | 14.83B | 4.15B | 10.68B | 9.05B |
| 3 | 81.73B | 7.6% | 36.0% | 19.13B | 4.10B | 15.03B | 11.72B |
| 4 | 87.32B | 6.8% | 42.0% | 23.84B | 3.99B | 19.85B | 14.25B |
| 5 | 92.65B | 6.1% | 42.0% | 25.29B | 3.81B | 21.48B | 14.19B |
| 6 | 97.65B | 5.4% | 42.0% | 26.66B | 3.57B | 23.09B | 14.04B |
| 7 | 102.20B | 4.7% | 42.0% | 27.90B | 3.25B | 24.65B | 13.80B |
| 8 | 106.23B | 3.9% | 42.0% | 29.00B | 2.88B | 26.12B | 13.46B |
| 9 | 109.66B | 3.2% | 42.0% | 29.94B | 2.45B | 27.49B | 13.04B |
| 10 | 112.40B | 2.5% | 42.0% | 30.68B | 1.96B | 28.73B | 12.54B |
Key risks
- IRA Medicare price negotiation and most-favored-nation pricing pressure on Skyrizi, Rinvoq and Vraylar
- Overpaying in business development (IPR&D write-offs) as AbbVie buys pipeline to cover late-2030s exclusivity losses
- $62B of net debt and dividend commitments limit flexibility if growth slows
- Competition from oral IL-23 and TL1A drugs in inflammatory bowel disease and psoriasis
Catalysts
- Rinvoq label expansions (alopecia areata, lupus, vitiligo) and Skyrizi share gains in IBD
- Emraclidine/tavapadon and oncology ADC readouts that show the post-2030 pipeline can carry growth